Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Amortization of Deferred Charges (2019 - 2020)

Historic Amortization of Deferred Charges for Akebia Therapeutics (AKBA) over the last 2 years, with Q1 2020 value amounting to -$647000.0.

  • Akebia Therapeutics' Amortization of Deferred Charges fell 537.46% to -$647000.0 in Q1 2020 from the same period last year, while for Mar 2020 it was -$2.3 million, marking a year-over-year change of. This contributed to the annual value of -$2.2 million for FY2019, which is N/A changed from last year.
  • Per Akebia Therapeutics' latest filing, its Amortization of Deferred Charges stood at -$647000.0 for Q1 2020, which was down 537.46% from -$556000.0 recorded in Q4 2019.
  • In the past 5 years, Akebia Therapeutics' Amortization of Deferred Charges registered a high of -$483000.0 during Q2 2019, and its lowest value of -$647000.0 during Q1 2020.